Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exagen Inc. - Common Stock (NQ:XGN)

2.750 +0.070 (+2.61%)
Streaming Delayed Price Updated: 9:54 AM EDT, Mar 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Exagen Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. to Participate in Upcoming Investor Conferences
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. Announces Select Preliminary 2025 Financial Results
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. Reports Strong Q3 2025 Results
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. to Participate in Third Quarter Investor Conferences
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. Reports Strong Q2 2025 Results
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. Appoints Chas McKhann to Board of Directors
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025
From Exagen Inc.
Via GlobeNewswire
News headline image
Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional Shares
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. Prices Public Offering of Common Stock
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. Announces Proposed Public Offering of Common Stock
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. to Participate in Upcoming Investor Conferences
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD
The milestone demonstrates AVISE CTD’s value and adoption within the rheumatologic community, clearly demonstrating superior laboratory testing for improved patient care 
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
Significant enhancements will equip clinicians with even more diagnostic clarity in the treatment of patients with autoimmune disease 
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. Reports Third Quarter 2024 Results
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen to Announce Third Quarter 2024 Results on November 12, 2024
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference
From Exagen Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.